Combined analysis of a serum mRNA/miRNA marker signature and CA 19-9 for timely and accurate diagnosis of recurrence after resection of pancreatic ductal adenocarcinoma

• Verfasst von: Buchholz, Malte [VerfasserIn]
• Verfasst von: Lausser, Ludwig [VerfasserIn]
• Verfasst von: Schenk, Miriam [VerfasserIn]
• Verfasst von: Earl, Julie [VerfasserIn]
• Verfasst von: Lawlor, Rita T. [VerfasserIn]
• Verfasst von: Scarpa, Aldo [VerfasserIn]
• Verfasst von: Sanjuanbenito, Alfonso [VerfasserIn]
• Verfasst von: Carrato, Alfredo [VerfasserIn]
• Verfasst von: Malats, Nuria [VerfasserIn]
• Verfasst von: Tjaden, Christin [VerfasserIn]
• Verfasst von: Giese, Nathalia [VerfasserIn]
• Verfasst von: Büchler, Markus W. [VerfasserIn]
• Verfasst von: Hackert, Thilo [VerfasserIn]
• Verfasst von: Kestler, Hans A. [VerfasserIn]
• Verfasst von: Gress, Thomas M. [VerfasserIn]
• Titel: Combined analysis of a serum mRNA/miRNA marker signature and CA 19-9 for timely and accurate diagnosis of recurrence after resection of pancreatic ductal adenocarcinoma
• Titelzusatz: a prospective multicenter cohort study
• Verf.angabe: Malte Buchholz, Ludwig Lausser, Miriam Schenk, Julie Earl, Rita T. Lawlor, Aldo Scarpa, Alfonso Sanjuanbenito, Alfredo Carrato, Nuria Malats, Christine Tjaden, Nathalia A. Giese, Markus Büchler, Thilo Hackert, Hans A. Kestler, Thomas M. Gress for the BioPaC consortium
• E-Jahr: 2025
• Jahr: April 2025
• Umfang: 11 S.
• Illustrationen: Illustrationen
• Fussnoten: Veröffentlicht: 25 October 2024 ; Gesehen am 28.04.2025
• Titel Quelle: Enthalten in: United european gastroenterology journal
• Ort Quelle: Hoboken, NJ : Wiley, 2013
• Jahr Quelle: 2025
• Band/Heft Quelle: 13(2025), 3 vom: Apr., Seite 353-363
• ISSN Quelle: 2050-6414
• DOI: doi:10.1002/ueg2.12676
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: CA 19-9
• Sach-SW: early detection
• Sach-SW: microRNA
• Sach-SW: pancreatic cancer
• Sach-SW: pancreatic ductal adenocarcinoma
• Sach-SW: tumor recurrence
• K10plus-PPN: 1923742795

Abstract

Background and Aims Timely and accurate detection of tumor recurrence in pancreatic ductal adenocarcinoma (PDAC) patients is an urgent and unmet medical need. This study aimed to develop a noninvasive molecular diagnostic procedure for the detection of recurrence after PDAC resection based on quantification of circulating mRNA and miRNA biomarkers in serum samples. Methods In a multicentric study, serum samples from a total of 146 patients were prospectively collected after resection. Samples were classified into a “No Evidence of Disease” and a “Recurrence” group based on clinical follow-up data. A multianalyte biomarker panel was composed of mRNAs and miRNA markers and simultaneously analyzed in serum samples using custom microfluidic qPCR arrays (TaqMan array cards). A diagnostic algorithm was developed combining a 7-gene marker signature with CA19-9 data. Results The best-performing marker combination achieved 90% diagnostic accuracy in predicting the presence of tumor recurrence (98% sensitivity; 84% specificity), clearly outperforming the singular CA 19-9 analysis. Moreover, time series data obtained by analyzing successively collected samples from 5 patients during extended follow-up suggested that molecular diagnosis has the potential to detect recurrence earlier than routine clinical procedures. Conclusions TaqMan array card measurements were found to be biologically valid and technically reproducible. The BioPac multianalyte marker panel is capable of sensitive and accurate detection of recurrence in patients resected for PDAC using a simple blood test. This could allow a closer follow-up using shorter time intervals than currently used for imaging, thus potentially prompting an earlier work-up with additional modalities to allow for earlier therapeutic intervention. This study provides a promising approach for improved postoperative monitoring of resected PDAC patients, which is an urgent and unmet clinical need.